Powderly, J., Cote, G., Flaherty, K., Szmulewitz, R. Z., Ribas, A., Weber, J., Loo, D., Baughman, J., Chen, F., Moore, P., Bonvini, E., Vasselli, J., Wigginton, J., Cohen, R., Burris, H., & Chmielowski, B. (n.d.). interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3. Journal for immunotherapy of cancer, 3, . http://access.bl.uk/ark:/81055/vdc_100135176961.0x000005